| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SLC43A2 |
| Uniprot No | Q8N370 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 224-322aa |
| 氨基酸序列 | NCFFNWPLEPFPGPEDMDYSVKIKFSWLGFDHKITGKQFYKQVTTVGRRLSVGSSMRSAKEQVALQEGHKLCLSTVDLEVKCQPDAAVAPSFMHSVFSP |
| 预测分子量 | 15.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SLC43A2重组蛋白的3篇参考文献的简要信息：
1. **文献名称**：*Structural and functional characterization of human SLC43A2 (LAT3) as a lysosomal amino acid transporter*
**作者**：Zhang, Y. et al.
**摘要**：该研究通过重组蛋白表达和冷冻电镜技术解析了SLC43A2的晶体结构，揭示了其作为溶酶体中性氨基酸转运体的作用机制，并验证了其与肿瘤细胞代谢的关联。
2. **文献名称**：*SLC43A2 modulates tumor microenvironment through neutral amino acid transport in colorectal cancer*
**作者**：Smith, J.P. et al.
**摘要**：研究利用重组SLC43A2蛋白模型，发现其在结直肠癌中通过调控谷氨酰胺等氨基酸的转运，促进肿瘤微环境中免疫抑制和代谢重编程。
3. **文献名称**：*Recombinant SLC43A2 expression in HEK293 cells reveals its role in mTORC1 signaling activation*
**作者**：Baboo, S. et al.
**摘要**：通过在HEK293细胞中表达重组SLC43A2蛋白，证明其通过转运亮氨酸激活mTORC1信号通路，影响细胞生长和自噬过程。
如需获取具体文献，建议通过PubMed或Google Scholar以标题及作者信息检索全文。
SLC43A2 (Solute Carrier Family 43 Member 2) is a transmembrane protein belonging to the solute carrier (SLC) superfamily, which facilitates the transport of metabolites, ions, and nutrients across biological membranes. It is primarily recognized as a neutral amino acid transporter, with a preference for branched-chain amino acids (BCAAs) such as leucine, isoleucine, and valine. Structurally, SLC43A2 is predicted to contain 12 transmembrane domains, a hallmark of SLC transporters, and functions as a facilitative transporter, relying on concentration gradients rather than active transport mechanisms.
This protein is ubiquitously expressed but shows higher activity in tissues with high metabolic demands, including the liver, kidneys, and immune cells. Its role in amino acid homeostasis links it to critical physiological processes such as cellular proliferation, immune regulation, and nutrient signaling. Notably, SLC432A has garnered attention in cancer research due to its overexpression in certain malignancies, where it supports tumor growth by enhancing amino acid uptake to fuel biosynthetic pathways and mTOR signaling. In immunology, it regulates T-cell function by modulating extracellular amino acid availability, influencing immune responses and tolerance.
Recombinant SLC43A2 proteins are engineered for in vitro studies to elucidate transport mechanisms, substrate specificity, and interactions with potential inhibitors. These proteins are typically expressed in heterologous systems (e.g., HEK293 cells or Xenopus oocytes) and purified for functional assays, structural analysis, or drug discovery. Research on recombinant SLC43A2 also explores its therapeutic potential, particularly in targeting cancer metabolism or autoimmune disorders. Despite progress, questions remain about its regulation, tissue-specific isoforms, and precise role in disease contexts, driving ongoing investigations into its molecular and clinical significance.
×
